Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific Inc. (TMO) is a global leader in life sciences, diagnostics, and laboratory innovation, providing essential tools for scientific research and healthcare advancements. This dedicated news hub offers investors and industry professionals timely updates on TMO's strategic initiatives, financial performance, and technological breakthroughs.
Access curated press releases and articles covering earnings reports, product launches, acquisitions, and partnerships. Our repository ensures you stay informed about developments in analytical technologies, diagnostic solutions, and biopharma services that shape the company's growth trajectory.
Discover updates across TMO's core operations: analytical instrumentation advancements, life science research tools, and specialty diagnostic innovations. Bookmark this page for streamlined access to verified information supporting informed analysis of Thermo Fisher's market position and industry impact.
Thermo Fisher Scientific has completed its acquisition of The Binding Site Group for £2.3 billion ($2.8 billion). This acquisition expands Thermo Fisher's Specialty Diagnostics segment, enhancing its capabilities in oncology testing for multiple myeloma. The Binding Site's offerings are crucial for early diagnosis and monitoring of blood cancers, significantly improving patient outcomes. The transaction is expected to boost adjusted earnings per share by $0.07 in 2023. Thermo Fisher continues to lead in serving science with a projected annual revenue of around $40 billion.
Thermo Fisher Scientific has announced the pricing of a €1.25 billion offering of euro-denominated senior notes. The offering includes €500 million of 3.200% senior notes due 2026 and €750 million of 3.650% senior notes due 2034. The expected closing date is on or about November 21, 2022. Proceeds from this offering will fund general corporate purposes, including acquisitions and debt refinancing. The company operates under an effective registration statement with the SEC, ensuring compliance and transparency for investors.
Thermo Fisher Scientific, trading under TMO, has announced the pricing of a $1.2 billion bond offering, which includes $600 million in senior notes due 2027 with a 4.800% interest rate and $600 million in senior notes due 2032 with a 4.950% interest rate. The offering is set to close by November 21, 2022, subject to standard conditions. Proceeds will support various corporate purposes, including debt repayment and acquisitions. The offering is managed by BofA Securities, Citigroup, and Deutsche Bank.
Thermo Fisher Scientific (NYSE: TMO) has authorized a substantial share repurchase program, amounting to $4 billion. This initiative allows for the repurchase of shares in the open market or through negotiated transactions, with no expiration date set for the authorization. This strategic move aims to enhance shareholder value and reflects the company's confidence in its strong financial position, supported by an annual revenue of approximately $40 billion.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of
Thermo Fisher Scientific has partnered with Society for Science to present the Junior Innovators Challenge, a leading middle school STEM competition. As the title sponsor, Thermo Fisher aims to enhance student engagement in STEM fields. Nearly 300 affiliated science fairs will nominate top-performing students for the competition, offering over $100,000 in awards, including a $25,000 top prize. This initiative aligns with Thermo Fisher's commitment to equitable access to STEM education.
Thermo Fisher Scientific has announced a significant $1.0 billion share repurchase program for Q4 2022, increasing total buybacks to $3.0 billion for the year. Additionally, the company has entered into an agreement to acquire The Binding Site Group for £2.25 billion (or $2.6 billion), a leader in specialty diagnostics. These moves are part of Thermo Fisher's strategic focus on capital deployment, which will total $6.1 billion in 2022.
Thermo Fisher Scientific (NYSE: TMO) has announced a definitive agreement to acquire The Binding Site Group for £2.25 billion (approximately $2.6 billion). This acquisition enhances Thermo Fisher's specialty diagnostics segment, especially in oncology testing for multiple myeloma, a rapidly growing diagnostics area. The Binding Site is recognized for its Freelite® diagnostic assays, projected to generate over $220 million in revenue for 2022, with an annual growth rate of around 10%. The transaction is expected to complete in the first half of 2023 and will be accretive to adjusted earnings per share by $0.07 in the first full year.
Thermo Fisher Scientific Inc. (NYSE: TMO) reported strong financial results for Q3 2022, with revenue reaching $10.68 billion, a 14% increase. GAAP diluted EPS was $3.79, down from $4.79 in the same quarter last year, while adjusted EPS was $5.08. The company generated $0.44 billion from COVID-19 testing. New product launches, including the Orbitrap Ascend Tribrid mass spectrometer, enhanced their market position. The firm has expanded its manufacturing capabilities and committed to sustainability by sourcing renewable energy.
FAQ
What is the current stock price of Thermo Fishr Sci (TMO)?
What is the market cap of Thermo Fishr Sci (TMO)?
